Bone-marrow-derived Sema3A can be found in serum in significant amounts; however, Lavi and colleagues found that its serum concentration drops significantly in patients with MM in advanced stage, but not in pre-neoplastic conditions, such as MGUS or SMM. This evidence concerns the gene SEMA3A and Miyoshi myopathy.